Lastly, two approved agents are used to treat r/r MM, the first of which, TALVEY (talquetamab-tgvs), is the first BsAb to target CD3 and the G protein–coupled receptor, family C, group 5, member D (GPRC5D). The gene discussed is GPRC5D; the disease is Miyoshi myopathy.